GSK plc (NYSE:GSK) Shares Acquired by Stockman Wealth Management Inc.

Stockman Wealth Management Inc. increased its stake in shares of GSK plc (NYSE:GSK) by 3.7% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 217,200 shares of the pharmaceutical company’s stock after acquiring an additional 7,683 shares during the period. Stockman Wealth Management Inc.’s holdings in GSK were worth $7,346,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC grew its holdings in GSK by 103.4% during the 2nd quarter. AQR Capital Management LLC now owns 26,363 shares of the pharmaceutical company’s stock valued at $1,015,000 after purchasing an additional 13,403 shares in the last quarter. SG Americas Securities LLC raised its position in shares of GSK by 167.3% in the 3rd quarter. SG Americas Securities LLC now owns 18,773 shares of the pharmaceutical company’s stock valued at $767,000 after purchasing an additional 11,749 shares in the last quarter. Diversified Trust Co purchased a new position in shares of GSK during the 3rd quarter valued at approximately $308,000. Brookstone Capital Management increased its stake in shares of GSK by 2.8% in the third quarter. Brookstone Capital Management now owns 26,457 shares of the pharmaceutical company’s stock worth $1,082,000 after buying an additional 718 shares during the last quarter. Finally, Ritholtz Wealth Management raised its holdings in GSK by 2.8% in the third quarter. Ritholtz Wealth Management now owns 78,540 shares of the pharmaceutical company’s stock valued at $3,211,000 after acquiring an additional 2,143 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Down 1.0 %

GSK opened at $36.03 on Friday. The stock’s 50 day moving average price is $34.25 and its 200 day moving average price is $37.57. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.53. The stock has a market cap of $74.68 billion, a P/E ratio of 22.66, a P/E/G ratio of 1.42 and a beta of 0.64. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, research analysts predict that GSK plc will post 4.07 earnings per share for the current year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a yield of 4.36%. GSK’s payout ratio is presently 93.08%.

Analyst Upgrades and Downgrades

GSK has been the topic of a number of recent analyst reports. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and cut their target price for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Six equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, GSK has a consensus rating of “Moderate Buy” and an average target price of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.